Corticosteroid therapy alone for the treatment of C3 glomerulonephritis in association with monoclonal gammopathy Journal Article


Authors: Sathick, I. J.; Zand, L.; Nasr, S. H.; Leung, N.
Article Title: Corticosteroid therapy alone for the treatment of C3 glomerulonephritis in association with monoclonal gammopathy
Abstract: Introduction: C3 glomerulonephritis (C3GN) is a form of proliferative glomerulonephritis characterized by dominant glomerular C3 deposition. There is currently no consensus guideline on therapy for this disease. Experience with corticosteroids alone is scant in C3GN. We report the experience of treating patients with C3GN in association with monoclonal gammopathy with corticosteroid at a single center. Materials and methocL Corticosteroid therapy alone was used to treat 6 patients with C3GN who were also found to have monoclonal gammopathy at the time of presentation. Results: Median age of this cohort was 65 years. Median estimated glomerular filtration rate (eGFR) by MDRD equation was 31.6 mL/min/1.73m(2) at presentation. After a median duration of follow-up of 23.5 months, all patients showed improvement in proteinuria: median proteinuria reduced from 2.3 to 0.5 g/d. Four of 6 patients showed improvement in kidney function. One patient who had required renal replacement therapy recovered renal function. Median eGFR at follow-up was 38.7 mL/min/1.73m(2). Discussion: In patients with C3GN in association with monoclonal gammopathy, corticosteroid therapy alone may be a viable treatment option. Work-up should be done to exclude a hematologic neoplasm and inherited complement abnormalities before proceeding to corticosteroid therapy.
Keywords: corticosteroid; immunosuppressive treatment; monoclonal gammopathy; mycophenolate-mofetil; glomerulopathy; c3 glomerulonephritis; renal significance
Journal Title: Clinical Nephrology
Volume: 91
Issue: 2
ISSN: 0301-0430
Publisher: Dustri-Verlag Dr. Karl Feistle  
Date Published: 2019-02-01
Start Page: 79
End Page: 86
Language: English
ACCESSION: WOS:000455883300003
DOI: 10.5414/cn109442
PROVIDER: wos
PUBMED: 30474593
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors